Mosunetuzumab: First Approval

Drugs. 2022 Jul;82(11):1229-1234. doi: 10.1007/s40265-022-01749-5.

Abstract

Mosunetuzumab (Lunsumio®), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies. This article summarizes the milestones in the development of mosunetuzumab leading to this first approval for relapsed or refractory follicular lymphoma.

Publication types

  • Review

MeSH terms

  • Adult
  • Antibodies, Bispecific* / pharmacology
  • Antibodies, Bispecific* / therapeutic use
  • Antigens, CD20
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Immunotherapy
  • Lymphoma, Follicular* / drug therapy

Substances

  • Antibodies, Bispecific
  • Antigens, CD20
  • Antineoplastic Agents